Drug
Efgartigimod Alfa Fcab
Efgartigimod Alfa Fcab: highest development phase Phase 2, developed by Argenx. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Argenx
Trials
| Drug | Phase | Indication |
|---|---|---|
| Efgartigimod Alfa-Fcab NCT05701189 | Phase 2 | Guillain-Barre Syndrome |
Latest
No recent events.
Follow Efgartigimod Alfa Fcab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.